QuidelOrtho Shares Plunge 20% After Weak Q1 Outlook

Diagnostic company cites slower flu season, China sales, and EMEA order delays as factors behind revenue miss.

Apr. 16, 2026 at 6:41am

Got story updates? Submit your updates here. ›

A high-contrast, black-and-white close-up image of intricate medical diagnostic equipment and machinery, conveying the complex, industrial nature of the healthcare technology that powers the industry.The complex machinery and technology that powers the diagnostic healthcare industry faces ongoing challenges, as seen in QuidelOrtho's recent revenue struggles.San Diego Today

QuidelOrtho Corporation's stock dropped over 20% in after-hours trading on Wednesday after the company reported preliminary Q1 2026 revenue in the range of $615 million to $620 million, missing expectations. The company cited a weaker respiratory season, slower China distributor sales, and delays in certain EMEA orders as factors behind the revenue shortfall. QuidelOrtho also expects negative free cash flow in the first half of 2026, though it anticipates positive full-year free cash flow.

Why it matters

As a major player in the diagnostic healthcare products market, QuidelOrtho's performance is seen as an indicator of broader industry trends. The company's struggles with respiratory illness testing and international sales suggest ongoing challenges in the sector, which could have wider implications for public health monitoring and medical supply chains.

The details

QuidelOrtho reported preliminary unaudited Q1 2026 revenue in the range of $615 million to $620 million, missing expectations. The company cited a 30% decline in U.S. Influenza-like Illness visits compared to the prior-year period, along with slower China distributor sales and delays in certain EMEA orders. Additionally, QuidelOrtho expects negative free cash flow in the first half of 2026, with Q1 free cash flow projected between $(65) million to $(70) million, though it anticipates positive full-year 2026 free cash flow.

  • QuidelOrtho reported preliminary Q1 2026 revenue on April 16, 2026.
  • The company is scheduled to release its full Q1 2026 results on May 5, 2026, after markets close.

The players

QuidelOrtho Corporation

A diagnostic healthcare products maker based in San Diego, California.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching QuidelOrtho's full Q1 2026 earnings report on May 5th for more details on the company's performance and outlook.

The takeaway

QuidelOrtho's struggles with respiratory illness testing and international sales highlight the ongoing challenges facing the diagnostic healthcare industry, which could have broader implications for public health monitoring and medical supply chains.